Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company” or "Solid”), a life sciences company developing precision genetic ...

FALCON is a first-in-human, open-label, multi-center Phase 1b clinical trial designed to evaluate the safety and tolerability ...

The California Institute for Regenerative Medicine (CIRM) has awarded $7.4 million to support a University of California San Diego team developing a first-of-its-kind stem cell-based gene therapy for ...

Welcome back to a new semester of Dissertation Diaries. As a reminder, this is the series where we highlight Ph.D. students ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular ...

SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected ...

Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for ...

Brits plagued by forgetfulness are being told to get their vitamin levels checked, as running low on a crucial nutrient can ...

Scientists at Johns Hopkins have uncovered a surprising new way to influence brain activity by targeting a long-mysterious class of proteins linked to anxiety, schizophrenia, and movement disorders.

One of SeaWorld San Diego’s first rescues of 2026 was in La Jolla following reports of a malnourished fur seal pup in the ...

The NHS has warned that vitamin B12 deficiency can cause neurological problems that may mimic dementia symptoms ...

Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for myotonic dystrophy type 1 (DM1), the most common adult-onset form of ...